Citations

Clear

2429 citation(s) found for "Shah, SS".

S735 Reasons for Treatment Discontinuation in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
Shah, Eric D. , Lacy, Brian E. , Chey, William D. , Mavrommatis, Evan, Li, Moming , Brenner, Darren M. , Shah, Eric D , Reid, Kayla, Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S505-S506

10.14309/01.ajg.0001032308.58999.cd Get It

Efficacy and toxicity analysis of selective BET bromodomain inhibitors in models of inflammatory liver disease
Doskey, Luke C. , Scholtz, Cole R. , Vail, Nora R. , Khanal, Shalil , Lee, Amani, Kandanur, Sai Giridhar Sarma , Hoell, Zachariah J. , Huehls, Amelia M. , Issa, Mohamed, Kostallari, Enis , Cao, Sheng , Shah, Vijay H. , Kostallari, Enis , Lee, Amani L. , Issa, Mohamed R , Reid, Joel M. , Malhi, Harmeet , Pomerantz, William C. K.

Mayo Clinic

No container title available | October 24, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.26434/chemrxiv-2024-lm1zq Get It

BET bromodomain inhibitors demonstrate significant promise as anti-inflammatory agents targeting a variety of inflammatory disorders. However, clinical data has demonstrated that the administration of non-selective BET bromodomain inhibitors has led to significant dose-limiting toxicity in clinical settings. More selective inhibitors of the second BET bromodomains, referred to as pan-D2 inhibitors, are better tolerated, however their efficacy varies significantly depending on disease indication. Here, we use three orally bioavailable inhibitors, 1–3, that are either selective for the first N-terminal bromodomain of BRD4 (BRD4-D1 selective), or pan-D1 biased, for assessing their cellular and in vivo efficacy and safety profile in two models of inflammatory liver disease. We compare their effects to known pan-D2 and pan-BET inhibitors. Our results show that pan-D1 biased inhibitor, 3, is as efficacious as the pan-BET inhibitor I-BET151 in reducing inflammation from LPS-induced and drug-induced toxicity, whereas pan-D2 inhibitors are less effective. BRD4-D1 selective inhibitors, 1 and 2, are also efficacious; however, new inhibitors with improved cellular target engagement will be necessary to more thoroughly assess their effects. Finally, BRD4-D1 selective inhibitors are better tolerated in a preclinical model of thrombocytopenia than pan-D1 biased inhibitors, while gastrointestinal (GI) toxicity may be a BRD4-driven effect. These results highlight the importance of assessing specific BET protein and bromodomain functions due to their varying roles in diverse disease models.
Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center
McHugh, Jack , Bayless, David R., Ranganath, Nischal , Kind, Dalton R., Wengenack, Nancy L. , Shah, Aditya , McHugh, Jack , Wengenack, Nancy L , Shah, Aditya S , Ranganath, Nischal , Bayless, David R., Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | October 23, 2024 | Volume: 62 | Issue: 11 | Pages: No page available

10.1128/jcm.01057-24 | PMID 39440933 Get It

ABSTRACT The prevalence of invasive candidiasis caused by non- albicans Candida species is increasing. Candida guilliermondii is an infrequent cause of candidemia but has been associated with decreased susceptibility to triazoles. Clinical data related to the infection with C. guilliermondii are sparse. Our study evaluated the antifungal susceptibility testing (AST) for C. guilliermondii isolates submitted to a reference laboratory over a 12-year period (2012–2023). AST patterns were examined using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cutoff values (ECVs) and breakpoints. Where isolates were identified from patients treated at our institution, retrospective chart review was performed to describe patient risk factors, treatment approaches, and outcomes associated with C. guilliermondii fungemia. One hundred twelve blood culture isolates of C. guilliermondii were identified, and clinical data were available for 21 fungemic patients. A significant number of isolates (9.8–20.5%) were observed to be non-wild type for various triazoles. All isolates were susceptible to micafungin. A majority (76.2%) of cases of C. guilliermondii fungemia treated at our tertiary care center were hospital-acquired, and two-thirds of patients were immunocompromised at the time of diagnosis. Ten of the 21 patients died within 60 days of fungemia, although mortality was directly or partially attributed to C. guilliermondii fungemia in only four cases (19.0%). Echinocandins may be used for empiric therapy for C. guilliermondii until the results of AST are available. Further research is required to determine appropriate clinical breakpoints for triazoles. IMPORTANCE Our study addresses a significant knowledge gap in the clinical management of this non- Candida albicans species. Our retrospective review includes comprehensive AST data for 112 Candida guilliermondii isolates, which is the largest number of isolates reported from the United States to date. Susceptibility data are supplemented by clinical outcomes, where isolates were identified for patients treated at Mayo Clinic. Key findings from our study include the observation that a notable proportion of C. guilliermondii isolates exhibit non-wild-type profiles for various triazoles. Importantly, all isolates remained susceptible to echinocandins, suggesting their efficacy as first-line therapy in the absence of timely susceptibility results. Furthermore, our study highlights the high mortality associated with C. guilliermondii fungemia in immunocompromised patients, emphasizing the urgent need for optimized treatment strategies.
Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease
Asatryan, Babken , Murray, Brittney , Tadros, Rafik , Shah, Ravi A. , Dabbagh, Ghaith Sharaf , Landstrom, Andrew P. , Dobner, Stephan , Munroe, Patricia B. , Haggerty, Christopher M. , Owens, Anjali , Semsarian, Christopher , Barth, Andreas S. , Roden, Dan M. , Ware, James S. , Investigators, the Genotype‐First Approach, Shah, Ravi A , Sharaf Dabbagh, Ghaith , Landstrom, Andrew P , Dobner, Stephan , Munroe, Patricia B , Haggerty, Christopher M , Medeiros-Domingo, Argelia , Owens, Anjali T , Kullo, Iftikhar J , Semsarian, Christopher , Reichlin, Tobias , Barth, Andreas S , Roden, Dan M. , James, Cynthia A , Ware, James S , Chahal, Choudhary Anwar A , Asatryan, Babken , Tadros, Rafik , Rieder, Marina , Medeiros‐Domingo, Argelia , Kullo, Iftikhar J. , James, Cynthia A. , Chahal, C. Anwar A. , Investigators, the Genotype‐First Approach

Mayo Clinic

Journal of the American Heart Association | October 18, 2024 | Volume: 13 | Issue: 21 | Pages: No page available

10.1161/jaha.123.033557 | PMID 39424414 Get It

Precision medicine, which among other aspects includes an individual's genomic data in diagnosis and management, has become the standard‐of‐care for Mendelian cardiovascular disease (CVD). However, early identification and management of asymptomatic patients with potentially lethal and manageable Mendelian CVD through screening, which is the promise of precision health, remains an unsolved challenge. The reduced costs of genomic sequencing have enabled the creation of biobanks containing in‐depth genetic and health information, which have facilitated the understanding of genetic variation, penetrance, and expressivity, moving us closer to the genotype‐first screening of asymptomatic individuals for Mendelian CVD. This approach could transform health care by diagnostic refinement and facilitating prevention or therapeutic interventions. Yet, potential benefits must be weighed against the potential risks, which include evolving variant pathogenicity assertion or identification of variants with low disease penetrance; costly, stressful, and inappropriate diagnostic evaluations; negative psychological impact; disqualification for employment or of competitive sports; and denial of insurance. Furthermore, the natural history of Mendelian CVD is often unpredictable, making identification of those who will benefit from preventive measures a priority. Currently, there is insufficient evidence that population‐based genetic screening for Mendelian CVD can reduce adverse outcomes at a reasonable cost to an extent that outweighs the harms of true‐positive and false‐positive results. Besides technical, clinical, and financial burdens, ethical and legal aspects pose unprecedented challenges. This review highlights key developments in the field of genotype‐first approaches to Mendelian CVD and summarizes challenges with potential solutions that can pave the way for implementing this approach for clinical care.
Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment
Singhal, Deepak , Hahn, Christopher N , Shah, Meera , Hiwase, Devendra , Kutyna, Monika M , Hahn, Christopher , Shah, Mithun V , Hiwase, Devendra , Singhal, Deepak , Kutyna, Monika

Mayo Clinic

Blood Cancer Discovery | October 18, 2024 | Volume: 5 | Issue: 6 | Pages: 400-416

10.1158/2643-3230.bcd-24-0103 | PMID 39422544 Get It

Abstract Therapy-related myeloid neoplasm (t-MN), characterized by its association with prior exposure to cytotoxic therapy, remains poorly understood and is a major impediment to long-term survival even in the era of novel targeted therapies due to its aggressive nature and treatment resistance. Previously, cytotoxic therapy–induced genomic changes in hematopoietic stem cells were considered sine qua non in pathogenesis; however, recent research demonstrates a complex interaction between acquired and hereditary genetic predispositions, along with a profoundly senescent bone marrow (BM) microenvironment. We review emerging data on t-MN risk factors and explore the intricate interplay among clonal hematopoiesis, genetic predisposition, and the abnormal BM microenvironment. Significance: t-MN represents a poorly understood blood cancer with extremely poor survival and no effective therapies. We provide a comprehensive review of recent preclinical research highlighting complex interaction among emerging therapies, hereditary and acquired genetic factors, and BM microenvironment. Understanding the risk factors associated with t-MN is crucial for clinicians, molecular pathologists, and cancer biologists to anticipate and potentially reduce its incidence in the future. Moreover, better understanding of the molecular pathogenesis of t-MN may enable preemptive screening and even intervention in high-risk patients.
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Selvaraj, Senthil , Patel, Shachi, McGarrah, Robert W. , Jones, Philip G. , Kwee, Lydia Coulter , Windsor, Sheryl L. , Ilkayeva, Olga , Muehlbauer, Michael J. , Newgard, Christopher B. , Kitzman, Dalane W. , Inzucchi, Silvio E. , Mentz, Robert J. , Kosiborod, Mikhail , Shah, Svati H. , Sauer, Andrew J , McGarrah, Robert , Jones, Philip G , Kwee, Lydia Coulter , Windsor, Sheryl L , Ilkayeva, Olga , Muehlbauer, Michael J , Newgard, Christopher B , Borlaug, Barry A , Kitzman, Dalane W , Shah, Sanjiv J , Margulies, Kenneth B. , Husain, Mansoor , Inzucchi, Silvio E , McGuire, Darren K , Lanfear, David E , Javaheri, Ali , Umpierrez, Guillermo E. , Mentz, Robert J , Sharma, Kavita , Kosiborod, Mikhail N , Shah, Svati , Borlaug, Barry A. , Husain, Mansoor , McGuire, Darren K. , Sharma, Kavita

Mayo Clinic

Circulation: Heart Failure | October 18, 2024 | Volume: 17 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.124.011980 | PMID 39421941 Get It

BACKGROUND: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though similar effects have not been observed in HF with preserved ejection fraction. We explore whether metabolic effects of SGLT2is vary across the left ventricular ejection fraction spectrum and their relationship with cardiometabolic end points in 2 randomized trials of dapagliflozin in HF. METHODS: Metabolomic profiling of 61 metabolites was performed in 527 participants from DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection Fraction) and PRESERVED-HF (Dapagliflozin in PRESERVED Ejection Fraction HF; 12-week, placebo-controlled trials of dapagliflozin in HF with reduced ejection fraction and HF with preserved ejection fraction, respectively). Linear regression was used to assess changes in principal components analysis–defined metabolite factors with treatment from baseline to 12 weeks, as well as the relationship between changes in metabolite clusters and HF-related end points. RESULTS: The mean age was 66±11 years, 43% were female, and 33% were self-identified as Black. Two principal components analysis–derived metabolite factors (which were comprised of ketone and short-/medium-chain acylcarnitines) increased with dapagliflozin compared with placebo. Ketosis (defined as 3-hydroxybutyrate >500 μM) was achieved in 4.5% with dapagliflozin versus 1.2% with placebo ( P =0.03). There were no appreciable treatment effects on amino acids, including branched-chain amino acids. Increases in several acylcarnitines were consistent across LVEF ( P interaction >0.10), whereas the ketogenic effect diminished at higher LVEF ( P interaction =0.01 for 3-hydroxybutyrate). Increases in metabolites reflecting mitochondrial dysfunction (particularly long-chain acylcarnitines) and aromatic amino acids and decreases in branched-chain amino acids were associated with worse HF-related outcomes in the overall cohort, with consistency across treatment and LVEF. CONCLUSIONS: SGLT2is demonstrate common (fatty acid) and distinct (ketogenic) metabolic signatures across the LVEF spectrum. Changes in key pathways related to fatty acid and amino acid metabolism are associated with HF-related end points and may serve as therapeutic targets across HF subtypes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifiers: NCT03030235 and NCT02653482.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Aldoss, Ibrahim , Kopmar, Noam E. , Lin, Chenyu , Dekker, Simone E. , Gupta, Vishal, O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Kate , Ahmed, Mohamed , Schwartz, Marc S. , Tracy, Sean , Mukherjee, Akash , Ladha, Abdullah , Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Pullarkat, Vinod , Muffly, Lori , Oliai, Caspian , Yaghmour, George , Sutherland, Katherine, Zambrano, Héctor, Bradshaw, Danielle , Kubiak, Michal , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Stefan, Maryann, O'Dwyer, Kristen M., Blunk, Betsy, Bishop, Michael R. , Aldoss, Ibrahim , Kopmar, Noam E , Lin, Chenyu , Gupta, Vishal K , Muhsen, Ibrahim N , Valtis, Yannis , Miller, Katharine , Chen, Evan , Mercadal, Santiago , Tracy, Sean I , Dholaria, Bhagirathbhai R , Battiwalla, Minoo , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Solh, Melham M , Kota, Vamsi , Frey, Noelle V , Park, Jae H , Luskin, Marlise R , Stock, Wendy , Cassaday, Ryan D , Muffly, Lori , Bachanova, Veronika , Roloff, Gregory W. , Ahmed, Naveed, Dykes, Kaitlyn C. , Schwartz, Marc, Dholaria, Bhagirathbhai , Battiwalla, Minoo , Hilal, Talal , Tsai, Stephanie B., Kota, Vamsi , Leonard, Jessica T , Frey, Noelle V. , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal , Faramand, Rawan , Oliai, Caspian H , Majhail, Navneet S. , Mathews, John Abraham , Advani, Anjali S. , O'Dwyer, Kristin , Lee, Catherine J , Bishop, Michael Russell

Mayo Clinic

Journal of Clinical Oncology | October 17, 2024 | Volume: 43 | Issue: 5 | Pages: 558-566

10.1200/jco.24.00321 | PMID 39418622 Get It

PURPOSE On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy. METHODS We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). RESULTS At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy. CONCLUSION Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.
P14.24.A USE OF OMMAYA RESERVOIR FOR INTRATHECAL CHEMOTHERAPY AND DISEASE MONITORING IN ROUTINE CLINICAL PRACTICE: ASSESSMENT OF SAFETY AND EFFICACY
Harahsheh, Ehab , Shah, Sahrish, Butterfield, Richard , Ariete, Carl, Lyons, Mark , Krishna, Chandan , Mrugała, Maciej M. , Ensign, Shannon P. Fortin , Zimmerman, R, Bendok, Bernard R.

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v83-v83

10.1093/neuonc/noae144.275 Get It

Abstract BACKGROUND Leptomeningeal disease (LMD) carries poor prognosis with an average survival of 3-6 months after diagnosis. Ommaya reservoirs (OR) are an accessible alternative to serial lumbar punctures for delivery of intrathecal chemotherapy (IC) and disease monitoring but are not widely used. Intraventricular administration of chemotherapy may be associated with superior efficacy and improved patient comfort. The purpose of this study was to assess safety and efficacy of IC and disease monitoring via OR in routine clinical practice. MATERIAL AND METHODS Patients who received at least one administration of IC via OR for LMD between 2017 and 2022 were included. Demographics, treatment type, complications and outcomes were recorded. RESULTS We identified 22 patients (17 females, 5 males) with mean age 50.9 ± 14.8 years. The primary tumors were: breast (12), leukemia (3), ovarian carcinoma (3), CNS lymphoma (1), urothelial carcinoma (1), spinal melanocytoma (1), and high-grade glioma (1). A total of 208 OR injections were performed [median was 9 OR injections per patient, interquartile range (IQR) (5, 13)]. Five patients (23%) experienced mild adverse events of grade 2 or lower by Common Terminology Criteria for Adverse Events. Overall risk of adverse event from injection was 3.4% (7/208). Eight patients (36.3%) converted into negative CSF cytology (median 1 month following first injection), and 18 patients (82%) had clinical or radiological progression of their LMD (median 2 months following first injection). Eleven patients (50%) died of their LMD during follow-up. Median OS and PFS from the first injection were 5.3 months [95% CI 4.8-NE (not estimable)] and 4.3 months [95% CI 1.8-16.0], respectively. CONCLUSION Use of OR in routine clinical practice is a safe and feasible option and should be strongly considered for treatment and frequent disease monitoring of patients with LMD, especially in the era of circulating tumor cells analysis. The median OS in our cohort is comparable to prior published series.
P14.05.A A PROSPECTIVE, MULTICENTER TRIAL OF FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
Ozair, Ahmad , Sahgal, Arjun , Groot, John Frederick De, Hibert, Matthew , Zhu, James , Achrol, Achal S. , Shah, Bhavya , Patel, Toral , Rincon-Toroella, Jordina, Sporrer, Justin, Hilliard, Justin D. , Bezchlibnyk, Yarema , Rezai, Ali R. , Lipsman, Nir , Woodworth, Graeme F., Ozair, Ahmad , Ahluwalia, Manmeet S. , Burns, Terry C. , McDermott, Michael , Mogilner, Alon Y. , Mishra, Mark V. , Everson, Richard G. , Weinberg, Jeffrey S. , Cifarelli, Christopher P.

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v77-v78

10.1093/neuonc/noae144.256 Get It

Abstract BACKGROUND Liquid biopsy in glioblastoma (GBM) is hindered by a lack of requisite circulating tumor (ct) and cell-free (cf) DNA levels in blood due to the blood-brain barrier (BBB). This limits the identification of blood-based tumor biomarkers along with the development and use of biomarker-driven systemic therapies. Real-time image-guided low intensity focused ultrasound (LIFU) combined with intravenously administered microbubble oscillators, leads to non-invasive disruption of the BBB. This trial aims to evaluate the utility of LIFU for boosting blood ctDNA and cfDNA for enhanced liquid biopsy in GBM patients. MATERIAL AND METHODS LIBERATE is an ongoing, prospective, multi-center, self-controlled, pivotal trial evaluating safety and technical efficacy of LIFU-based BBB disruption for increasing blood ctDNA and cfDNA levels in adults, aged 18-80 years with GBM. Patients with suspected GBM planned for tumor biopsy or resection at ten centers in the US are being enrolled. Patients with multifocal tumors or tumors arising from deep midline, thalamus, cerebellum, or brainstem are excluded. Patients are administered IV microbubbles for enhanced sonication effects, after which MR-guided BBB disruption using a 220 kHz LIFU device is performed with real-time acoustic feedback control for effective microbubble activation. Before and after procedure, phlebotomy and MRI brain are performed to evaluate outcomes. Primary study endpoint is defined, per subject, as ratio between their cfDNA level in blood 1-hour post-LIFU procedure compared to cfDNA level in blood pre-procedure. Primary study hypothesis is that BBB disruption with LIFU leads to a ≥2-fold rise in blood cfDNA. The secondary hypothesis is that there exists ≥75% agreement between biomarker pattern in blood cfDNA sample obtained 1-hour post-LIFU and the biomarker pattern in tumor tissue obtained later. The trial has been powered to evaluate both primary and secondary hypotheses. Based on an assumed true agreement rate of 91% and a one-sided alpha of 0.025, an exact test for binomial proportions provides a sample of N = 50 with 84% power for the secondary hypothesis. Exploratory endpoints include (1) sensitivity of detection of known specific somatic mutations in ctDNA from blood samples collected before and after LIFU, (2) estimation of ctDNA levels post-LIFU in samples collected at 30 minutes, 1 hour, 2 hour, and 3 hour to determine the time of greatest yield, (3) correlation of MRI parameters related to grading of BBB disruption and ctDNA-based biomarkers from post-LIFU blood samples. RESULTS Patient enrollment commenced in 2022, and 22 patients have been recruited by 05/2024. CONCLUSION Findings from this trial will be critical to liquid biopsy in GBM (Clinical trial information: NCT05383872).
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Mattison, Ryan J. , Abdelmessieh, Peter, Burke, Patrick W. , DeAngelo, Daniel J., Dinner, Shira, Fathi, Amir T. , Haddadin, Michael , Kirby, Suzanne, Liedtke, Michaela , Litzow, Mark R. , Long, Meixiao, Luger, Selina M. , Mangan, James K. , Massaro, Stephanie, May, William , Park, Jae H. , Schwartz, Marc S. , Shami, Paul J. , Tomlinson, Benjamin , Webster, Jonathan , Stehman, Katie, Shah, Bijal , Abboud, Ramzi , Aldoss, Ibrahim , DeAngelo, Daniel J. , Gauthier, Jordan , Jain, Nitin , Jonas, Brian A. , Logan, Aaron C , Oluwole, Olalekan O. , Przespolewski, Amanda , Rangaraju, Sravanti , Saygin, Caner , Schwartz, Marc, Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 563-576

10.6004/jnccn.2024.0051 | PMID 39413812 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.